Evidence map›Paper›PMID 30258136›Full record

ArticleNature2018

Combination therapy with anti-HIV-1 antibodies maintains viral suppression.

Pilar Mendoza, Henning Gruell, Lilian Nogueira, Joy A Pai, Allison L Butler, Katrina Millard, Clara Lehmann, Isabelle Suárez, Thiago Y Oliveira, Julio C C Lorenzi and 26 more

3 registry-linked trialsAbstract readClinical Trial, Phase IMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 370 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
370citing papers in PubMed, 4 pooled it
33.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03831945 phase1terminatednot on this mapstarted 2019, after this paper: background citation

An Exploratory Study of Combination Therapy With VRC-HIVMAB060-00-AB (VRC01) and 10-1074 in HIVInfected Individuals Undergoing Sequential Treatment Interruptions

TypeinterventionalSponsorNational Institute of Allergy and Infectious Diseases (NIAID)Ran2019 to 2020Enrolled27ConditionsHIVArmsVRC-HIVMAB060-00-AB (VRC01), 10-1074, Normal Saline Placebo
NCT04319367 phase2recruitingnot on this mapstarted 2021, after this paper: background citation

A Randomised Placebo Controlled Trial of ART Plus Dual Long-acting HIV-specific Broadly Neutralising Antibodies (bNAbs) vs ART Plus Placebo in Treated Primary or Early Stage HIV Infection on Viral Control Off ART

TypeinterventionalSponsorImperial College LondonRan2021 to 2027Enrolled72ConditionsHIV/AIDS and InfectionsArmsInvestigational Medicinal Product
NCT05612178 phase1active not recruitingnot on this mapstarted 2023, after this paper: background citation

A Randomized Placebo-controlled Study to Evaluate the Safety and Effects of Repeated Doses of 3BNC117-LS and 10-1074-LS on Persistent Viral Reservoirs in People Living With HIV and on Suppressive Antiretroviral Therapy

TypeinterventionalSponsorNational Institute of Allergy and Infectious Diseases (NIAID)Ran2023 to 2027Enrolled105ConditionsHIV-1Arms3BNC117-LS, 10-1074-LS, Sterile Saline
3 · Its place in the literature

Who cites it

370 citing papers in PubMed, 4 syntheses or guidelines pooled it, 536 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Trial
  19. Article
  20. Article

310 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

36 authors at 10 institutions in 2 countries.

Pilar Mendoza *Laboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA.
Henning Gruell *Laboratory of Experimental Immunology, Institute of Virology, University Hospital Cologne, Cologne, Germany.
Lilian NogueiraLaboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA.
Joy A PaiLaboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA.
Allison L ButlerLaboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA.
Katrina MillardLaboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA.
Clara LehmannDepartment I of Internal Medicine, University Hospital Cologne, Cologne, Germany.
Isabelle SuárezDepartment I of Internal Medicine, University Hospital Cologne, Cologne, Germany.
Thiago Y OliveiraLaboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA.
Julio C C LorenziLaboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA.
Yehuda Z CohenLaboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA.
Christoph WyenDepartment I of Internal Medicine, University Hospital Cologne, Cologne, Germany.
Tim KümmerleDepartment I of Internal Medicine, University Hospital Cologne, Cologne, Germany.
Theodora KaragounisLaboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA.
Ching-Lan LuLaboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA.
Lisa HandlMethods in Medical Informatics, Department of Computer Science, University of Tübingen, Tübingen, Germany.
Cecilia Unson-O'BrienLaboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA.
Roshni PatelLaboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA.
Carola RupingLaboratory of Experimental Immunology, Institute of Virology, University Hospital Cologne, Cologne, Germany.
Maike SchlotzLaboratory of Experimental Immunology, Institute of Virology, University Hospital Cologne, Cologne, Germany.
Maggi Witmer-PackLaboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA.
Irina ShimeliovichLaboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA.
Gisela KremerDepartment I of Internal Medicine, University Hospital Cologne, Cologne, Germany.
Eleonore ThomasDepartment I of Internal Medicine, University Hospital Cologne, Cologne, Germany.
Kelly E SeatonDuke Human Vaccine Institute, Duke University, Durham, NC, USA.
Jill HorowitzLaboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA.
Anthony P WestDivision of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA, USA.
Pamela J BjorkmanDivision of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA, USA.
Georgia D TomarasDuke Human Vaccine Institute, Duke University, Durham, NC, USA.
Roy M GulickDivision of Infectious Diseases, Weill Cornell Medicine, New York, NY, USA.
Nico PfeiferMethods in Medical Informatics, Department of Computer Science, University of Tübingen, Tübingen, Germany.
Gerd FätkenheuerDepartment I of Internal Medicine, University Hospital Cologne, Cologne, Germany.
Michael S SeamanCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
Florian Klein *Laboratory of Experimental Immunology, Institute of Virology, University Hospital Cologne, Cologne, Germany. florian.klein@uk-koeln.de.
Marina Caskey *Laboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA. mcaskey@rockefeller.edu.
Michel C Nussenzweig *Laboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA. nussen@rockefeller.edu.
Rockefeller University · USUniversity Hospital Cologne · DECalifornia Institute of Technology · USDuke University · USBeth Israel Deaconess Medical Center · USCornell University · USGerman Center for Infection Research · DEMax Planck Institute for Informatics · DEUniversity of Cologne · DEUniversity of Tübingen · DE

Funding

Support Component D/Vaccine Discovery, Concept to ClinicUM1AI100663 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI BAROUCH, DAN H. · 2012 to 2018
$131.5M
Patient and Population Health Outcomes Research SWGP30AI124414 · NIAID · ALBERT EINSTEIN COLLEGE OF MEDICINE, INC · PI Kathryn M. Anastos · 2017 to 2026
$28.3M
First-in-human study of two anti-SARS CoV-2 antibodies in health volunteersUM1AI126620 · NIAID · WISTAR INSTITUTE · PI MONTANER, LUIS J, RILEY, JAMES L. · 2016 to 2021
$24.5M
Optimization of Fc effector activity of anti-HIV antibodies to target HIV reservoirR01AI129795 · NIAID · ROCKEFELLER UNIVERSITY · PI NUSSENZWEIG, MICHEL C, RAVETCH, JEFFREY VICTOR · 2017 to 2021
$4.2M
Howard Hughes Medical InstituteNIAID NIH HHS P30 AI124414NIAID NIH HHS R01 AI129795NIAID NIH HHS UM1 AI100663NIAID NIH HHS UM1 AI126620
6 · The paper itself

Abstract

Individuals infected with HIV-1 require lifelong antiretroviral therapy, because interruption of treatment leads to rapid rebound viraemia. Here we report on a phase 1b clinical trial in which a combination of 3BNC117 and 10-1074, two potent monoclonal anti-HIV-1 broadly neutralizing antibodies that target independent sites on the HIV-1 envelope spike, was administered during analytical treatment interruption. Participants received three infusions of 30 mg kg

Indexed as

AdolescentAdultAgedAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntibodies, NeutralizingAnti-HIV AgentsBinding Sites, AntibodyBroadly Neutralizing AntibodiesCarrier StateDrug CombinationsDrug Resistance, ViralFemaleHistorically Controlled StudyHIV-1HIV Antibodies3BNC117 antibodyAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntibodies, NeutralizingAnti-HIV AgentsBroadly Neutralizing AntibodiesDrug Combinationsgp160 protein, Human immunodeficiency virus 1HIV AntibodiesHIV Envelope Protein gp160

Identifiers

PMID30258136
PMCPMC6166473
OpenAlexW2890205877

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.